Weight-Loss Drugs Earn Piles, Boatloads, and Oodles

As a simple search reveals, what are loosely called GLP-1 drugs have been a hot topic for a long time. Many people make plenty of profit from them, but published reports indicate some dissatisfaction among companies and individuals who would prefer, rather than a mere plenitude, to reap piles, boatloads, and oodles of money instead. As one authority explains,
GLP-1 is the natural hormone that your body makes… Semaglutide is the medicine that copies what your natural hormone does… You are not taking the hormone itself. You are taking a medicine that knows how to do the exact same job as the hormone.
The Garrison Center, a renowned think tank, has been calling public attention to matters related to semaglutide, to the point where some characterize this focused attention as whistleblowing. The colorful metaphor is borrowed from sports, where when an official lets out a blast on his whistle, that constitutes a ruling that the action taken by a player on either team was outside the realm of actions permitted in the game.
The trouble started because, although Novo Nordisk holds a patent on semaglutide, when there was an officially-declared shortage, another outfit was allowed to make and sell it too. Thomas L. Knapp thoroughly explains what happened when the telehealth company Hims & Hers had the temerity to sell semaglutide at a lower price than the rightful patent holder. Given that Hims & Hers would not even be allowed to market the stuff in the first place, had an exception not been made, this was regarded as a very hostile move.
The Novo Nordisk legal team pointed out that not only was the shortage officially declared over, erasing the justification for letting the other company sell the product, but something else was glaringly wrong, namely:
The fact is that their medicines are untested, and they’re putting patients at risk.
At this point, the whole narrative takes an unexpected turn, and journalist Knapp points out an absurdity:
[T]he difference between semaglutide from Hims & Hers and semaglutide from Novo Nordisk is the name on the label.
Novo Nordisk was charging around $150 a month, and Hims & Hers aspired to sell the same amount of the identical product for about $50 a month. But that detail is minor, compared to another matter, described as follows:
The whole POINT of Novo Nordisk’s attempt to enforce its patent is to CREATE a shortage of semaglutide in pill form… The patent, if enforceable, allows Novo Nordisk to charge customers AT LEAST three times as much for its pill as the market says it can be sold profitably for. Hims & Hers wouldn’t offer it for $50 if it expected to lose money doing so.
The purpose of patents, Knapp explains, is…
[…] to create artificial shortages so that inventors don’t have to compete with others who may copy their inventions — or even independently invent similar things… While I’m skeptical for the wildest claims about the benefits of GLP-1s, they’re clearly beneficial to enough people, in enough ways, that we should ask why governments are handing out price-gouging opportunities, in the form of monopolies, on them.
This is a gnarly situation whose resolution could resonate far and wide, affecting much more than this tempest in an industrial teapot. Meanwhile, despite widespread and fanatical acceptance, it is totally possible that the entire semaglutide market, which may have promised too much too soon, could totally collapse.
Your responses and feedback are welcome!
Source: “Is GLP-1 the Same as Semaglutide?,” SemaglutideMedics.org, 11/13/25
Source: “Semaglutide: Artificial shortage is Novo Nordisk’s business model,” TheGarrisonCenter.org, 02/10/26
Image by Peggy_Marco/Pixabay









FAQs and Media Requests: